Full Press Release Details
Total revenues of €77.0 M (+17%)
R&D revenues of €31.5 M (+38%) driven by alliance milestones
BioFocus DPI recurrent segment profit of €3.4 M
Group net loss decreased 33% to €14.6 M
Cash position of €27.3 M at year-end
Continued strong progress expected in 2009:
o revenues €100 M, year-end cash €20 M, increased profit BioFocus DPI
o three clinical programs, including first-in-class rheumatoid arthritis drug
Click here to access the live audio webcast presentation at 10.00 CET, call number +32 2290 1791